A Case of Superimposed Viral Myocarditis in a Patient with Systemic Lupus Erythematosus.
10.4070/kcj.2003.33.12.1147
- Author:
Bong Geun SONG
1
;
Byung Kwan LIM
;
Min Hyung KIM
;
Sung Chul SHIN
;
Jae Hong JUNG
;
Dong Hee KIM
;
Jeong Hwan KIM
;
Keon Woo PARK
;
Eun Mi KOH
;
Eun Seok JEON
Author Information
1. Department of Medicine, Sungkyunkwan University School of Medicine, Seoul, Korea.
- Publication Type:Case Report
- Keywords:
Myocarditis;
Coxsackievirus;
Systemic lupus erythematosus
- MeSH:
Adrenal Cortex Hormones;
Adult;
Azathioprine;
Cyclophosphamide;
Dyspnea;
Enterovirus;
Female;
Heart Failure;
Horses;
Humans;
Immunosuppressive Agents;
Lupus Erythematosus, Systemic*;
Myocarditis*;
Neutralization Tests
- From:Korean Circulation Journal
2003;33(12):1147-1150
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Lupus myocarditis is usually treated using immunosuppressive agents, such as high-dose corticosteroids, azathioprine and cyclophosphamide. Viral myocarditis and enteroviruses have been identified as the most common causative agents of myocarditis in lupus patients. Although immunosuppressive therapy has an important role in the treatment of lupus myocarditis, it is not recommended in patients with infectious or post-infectious viral myocarditis, and supportive care is very important in these patients. A 25-year old female patient, with systemic lupus erythematosus, was admitted due to severe dyspnea, and diagnosed as having heart failure. She recovered 7 days after supportive care for heart failure, without Immuno-suppression. Her sera neutralized coxsackievirus B3 (CVB3) in neutralization test, with the horse anti-CVB3 antibody (Ab, ATCC V030-501-560) used as a positive control. The titers for the neutralizing Ab in her sera were 4 times higher than that of the standard control ATCC Ab.
